XBiotech Inc(XBIT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:00 PM ET (Korea 10/29 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.48 | Insider Own | 36.87% | Shs Outstand | 30.5M | Perf Week | - |
| Market Cap | 0.06B | Forward P/E | - | EPS next Y | - | Insider Trans | 3.39% | Shs Float | 19.3M | Perf Month | -8.72% |
| Enterprise Value | -0.05B | PEG | - | EPS next Q | - | Inst Own | 6.5% | Short Float | 1.56% | Perf Quarter | -11.16% |
| Income | -0.05B | P/S | - | EPS this Y | - | Inst Trans | -0.56% | Short Ratio | 6.06 | Perf Half Y | -21.03% |
| Sales | 0.00B | P/B | 0.47 | EPS next 5Y | - | ROA | -28.9% | Short Interest | 0.30M | Perf YTD | -16.74% |
| Book/sh | 4.21 | P/C | 0.55 | EPS past 3/5Y | -11.39% -32.63% | ROE | -29.94% | 52W High | -42.15% ($3.44) | Perf Year | -16.74% |
| Cash/sh | 3.59 | P/FCF | - | Sales past 3/5Y | - | ROIC | -35.13% | 52W Low | 9.94% ($1.81) | Perf 3Y | -50.25% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -60.25% | Gross Margin | - | Volatility(W/M) | 4.72% 3.98% | Perf 5Y | -86.12% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.1 | Perf 10Y | -83.11% |
| Dividend Ex-Date | 2021/7/15 | Quick Ratio | 33.15 | EPS Q/Q | -283.16% | Profit Margin | - | RSI (14) | 41.18 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 33.15 | Sales Q/Q | - | SMA20 | -5.01% ($2.09) | Beta | 0.74 | Target Price | $28 |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -8.21% ($2.17) | Rel Volume | 6.24 | Prev Close | $1.85 |
| Employees | 85 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -14.64% ($2.33) | Avg Volume(3M) | 0.05M | Price | $1.99 |
| IPO | 2015/4/15 | Option/Short | Yes/Yes | Trades | 760 | Volume | 309,834 | Change | 7.57% |
🧬 A US clinical-stage biotech company developing therapeutics for cancer, infectious diseases, and inflammatory conditions through its proprietary 'True Human™' antibody platform. Through its next-generation anti-IL-1α antibody 'Natrunix,' the company aims to establish a new standard of care for patients with hard-to-treat pancreatic cancer and chronic diseases.
Over the past 1 year, on the lower side
42% below its 1-year high.
Traded more than usual. That is 624% of its average volume.
XBIT has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -86.1%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 6.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #398 of 594 in the industry
Based on market cap of $61M.
FAQ
What kind of company is XBIT?
XBIT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of XBIT?
The market cap of XBIT is approximately $61M, ranking 4,749 within its sector.
What is the 52-week high and low for XBIT?
XBIT has recorded a 52-week high of $3.44 and a low of $1.81.
